Borsini, Alessandra http://orcid.org/0000-0003-4410-7865
Merrick, Blair http://orcid.org/0000-0002-6061-6064
Edgeworth, Jonathan
Mandal, Gargi http://orcid.org/0000-0001-5767-4207
Srivastava, Deepak P. http://orcid.org/0000-0001-6512-9065
Vernon, Anthony C. http://orcid.org/0000-0001-7305-1069
Nebbia, Gaia
Thuret, Sandrine http://orcid.org/0000-0003-1260-8083
Pariante, Carmine M. http://orcid.org/0000-0002-9132-5091
Funding for this research was provided by:
Rosetrees Trust (M970)
RCUK | Medical Research Council (MR/J002739/1, MR/N029488/1, MR/J002739/1, MR/N029488/1)
EC | Horizon 2020 Framework Programme (848158)
Article History
Received: 11 February 2022
Revised: 29 July 2022
Accepted: 10 August 2022
First Online: 5 October 2022
Competing interests
: AB, CMP and ST have received research funding from Johnson & Johnson for research on depression and inflammation which included cellular work (2012–2018), but this work is unrelated to that funding; moreover, less than 10% of Professor Pariante’s support in the last 10 years derives from commercial collaborations, including: a strategic award from the Wellcome Trust (Neuroimmunology of Mood Disorders and Alzheimer’s Disease (NIMA) Consortium, grant 104025), in partnership with Janssen, GlaxoSmithKline, Lundbeck and Pfizer; and consultation and speakers fees from Boehringer Ingelheim, Eli Lilly, Compass, Eleusis, GH Research, Lundbeck, and Värde Partners. ST received funding for a project on neural stem cell aging co-funded by the UK Medical Research Council and Merck Sharp & Dohme Corp. The work presented in this paper is unrelated to these awards. BM, JE, GM, DPS, ACV and GN have no conflicts of interest to declare.